Skip to content

Addiction: all studies

Page 802 of 860: studies 8,011 to 8,020 of 8,594, newest first. Back to the addiction overview

Research

Repeated exposure to Δ9-tetrahydrocannabinol reduces prefrontal cortical dopamine metabolism in the rat

April 10, 1998 J. Jentsch, Christopher D. Verrico, D. Le et al.

Long-term abuse of marijuana by humans can induce profound behavioral deficits characterized by cognitive and memory impairments. In particular, deficits on tasks dependent on frontal lobe function have been reported in cannabis abusers. In the current study, we examined whether long-term exposure to delta9-tetrahydrocannabinol, the active ingredient in marijuana, altered the neurochemistry of...

The acute effects of amphetamine derivatives on extracellular serotonin and dopamine levels in rat nucleus accumbens.

Pharmacology, Biochemistry, and Behavior April 1998 Aino Kankaanpää, E Meririnne, P Lillsunde et al.

The acute effects of amphetamine derivatives on extracellular concentration of serotonin (5-HT) and dopamine in the nucleus accumbens were studied with in vivo microdialysis using conscious, freely moving rats. 5-HT, dopamine, and their major metabolites were measured by HPLC with electrochemical detection. Amphetamine (1.0-9.0 mg/kg) elevated dopamine levels considerably, but failed to affect...

Investigation of hallucinogenic and related beta-carbolines.

Drug and Alcohol Dependence April 1, 1998 B Grella, M Dukat, R Young et al.

Certain beta-carbolines are known to be hallucinogenic in humans, and several produce stimulus effects in animals similar to those of the classical hallucinogen 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM). Classical hallucinogens bind at 5-HT2 serotonin receptors and these receptors are thought to play a role in their mechanism of action. In the present study, we examined the binding...

The effects of beta-carbolines in rats trained with ibogaine as a discriminative stimulus.

European Journal of Pharmacology March 19, 1998 Scott Helsley, R A Rabin, Jerrold C Winter 6 citations

The structural features and hallucinogenic properties shared by ibogaine and certain beta-carbolines prompted the evaluation of several representative beta-carbolines in rats trained with ibogaine as a discriminative stimulus. In a previous report from our laboratory harmaline completely substituted for ibogaine (83.5%). In the present study, only 6-methoxyharmalan completely substituted...

DOI: 10.1016/s0014-2999(98)00002-8 (opens in new tab) Full text (opens in new tab) Ibogaine: ibogaine effects Ibogaine-like effect Beta-carbolines: natural compounds 6-methoxyharmalan +7

Story-like organization of dream experience in different periods of REM sleep.

Journal of Sleep Research March 1, 1998 Carlo Cipolli, R Bolzani, Giovanni Tuozzi

Four dream reports, collected from each of 16 subjects in an experimental night, were analysed using the criteria of Mandler and Johnson's story grammar. The experimental night was the first of the four nights where subjects had spontaneously given a dream report after each of the four awakenings planned in REM sleep. A multivariate analysis of covariance, taking the order of the nights where...

The effects of sigma, PCP, and opiate receptor ligands in rats trained with ibogaine as a discriminative stimulus.

Pharmacology, Biochemistry, and Behavior February 1, 1998 Scott Helsley, R A Filipink, W D Bowen et al. 16 citations

Although the mechanism of action of ibogaine, a hallucinogen that may be useful in the treatment of addiction, remains unknown, receptor binding studies suggest that ibogaine produces its effects via interactions with multiple receptor types. In addition to serotonergic receptors, which have been studied previously with respect to ibogaine, likely candidates include opiate, sigma (sigma), and...

DOI: 10.1016/s0091-3057(97)00454-1 (opens in new tab) Full text (opens in new tab) Ibogaine compound Ibogaine action Ibogaine effects Addiction treatment +15

Analysis of the medical use of marijuana and its societal implications.

Journal of the American Pharmaceutical Association 1998 H G Taylor

To review the pharmacology, therapeutics, adverse effects, and societal implications of the medical use of marijuana. MEDLINE and manual searches of English-language marijuana literature, supplemented with interviews of scientists currently conducting cannabinoid research. Search terms included pain OR palliative care AND cannabis or ALL marijuana; cachexia OR appetite OR appetite stimulants;...

Serotonergic function after (±)3,4-methylene-dioxymethamphetarnine (‘Ecstasy’) in humans

International Clinical Psychopharmacology 1998 Gilberto Gerra, Amir Zaimovic, Giuliano Giucastro et al. 145 citations

(+/-)3,4-Methylene-dioxymethamphetamine (MDMA, or 'Ecstasy') effects on serotonin system function and behaviour in humans are unclear. Fifteen MDMA users, who did not have other drug dependencies or alcohol abuse, and had not used other drugs for prolonged periods, and 15 control individuals were included in a study to assess the biological and psychological changes after chronic use of MDMA....

Is the Use of Ecstasy and Hallucinogens Increasing?

European Addiction Research 1998 Peter Schuster, Roselind Lieb, Christina Maria Lamertz et al. 96 citations

This report presents findings of a community survey of 3,021 adolescents and young adults aged 14–24 years in Munich, Germany, carried out to determine the prevalence of use and abuse of and dependence on ecstasy, amphetamines and hallucinogens. The response rate was 71%. <b>Results:</b> (1) In 1995, 4% of the male and 2.3% of the female respondents aged 14–24 reported the use of ecstasy....

Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys.

Pharmacology, Biochemistry, and Behavior December 1997 J L Wiley, K M Golden, W J Ryan et al.

In previous research arachidonylethanolamide (anandamide) has been shown to produce behavioral effects in mice characteristic of psychoactive cannabinoids, including antinociception, catalepsy, hypothermia, and hypomotility. However, differences have also been found between anandamide and delta9-tetrahydrocannabinol (delta9-THC), with anandamide having lower potency, a more rapid onset, and...